In solid organ transplant recipients, skin cancer risk associated with post-transplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to agents used post-transplant, other classes of immunosuppressants also have the potential to raise the risk…

Immunosuppression is a well-documented risk factor for skin cancer, as exemplified by the 65 to 250-fold higher squamous cell carcinoma risk, 10-fold higher basal cell carcinoma risk, and 0 to 8-fold higher melanoma risk in solid organ transplant recipients (SOTRs)…

Human monkeypox has become increasingly frequent worldwide since the outbreak was first reported in May 2022.

Ruxolitinib cream demonstrated safety and efficacy over 8 weeks in two double-blind phase 3 atopic dermatitis studies (NCT03745638/NCT03745651).